Latest on clinical benefit of tramiprosate in Alzheimer's

23 June 2017

Positive results published today by closely-held US biotech firm Alzheon, in The Journal of the Prevention of Alzheimer’s Disease (JPAD,) describe analyses of Phase III data for the investigational amyloid-targeted drug, tramiprosate, in patients with Alzheimer’s disease (AD).

The new analyses group patients according to APOE4 genotype and disease severity, and show tramiprosate’s largest efficacy signals in APOE4/4 homozygous patients with Mild Alzheimer’s disease. This preferential efficacy in APOE4/4 patients at the Mild stage of AD is consistent with the role of APOE4 and beta amyloid (Aβ) in AD, which includes the following key observations:

APOE4/4 patients have a higher burden of Aβ oligomers compared to APOE4 non-carriers;
soluble toxic Aβ oligomers play a key role early in the Alzheimer’s disease process; and
tramiprosate inhibits formation of Aβ oligomers at clinically relevant concentrations achieved in AD patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK